A new trading day began on Monday, with Century Therapeutics Inc (NASDAQ: IPSC) stock price down -4.10% from the previous day of trading, before settling in for the closing price of $1.22. IPSC’s price has ranged from $1.14 to $5.51 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -14.25%. Meanwhile, its annual earnings per share averaged 30.64%. With a float of $34.81 million, this company’s outstanding shares have now reached $84.76 million.
The extent of productivity of a business whose workforce counts for 165 workers is very important to gauge. In terms of profitability, gross margin is -404.17%, operating margin of -4925.59%, and the pretax margin is -4869.53%.
Century Therapeutics Inc (IPSC) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Century Therapeutics Inc is 59.06%, while institutional ownership is 31.01%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,267. In this transaction Chief Operations Officer of this company sold 1,033 shares at a rate of $1.23, taking the stock ownership to the 135,130 shares. Before that another transaction happened on Nov 04 ’24, when Company’s SVP Finance & Operations sold 283 for $1.23, making the entire transaction worth $347. This insider now owns 317,147 shares in total.
Century Therapeutics Inc (IPSC) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.64% per share during the next fiscal year.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Here are Century Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.76 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
The latest stats from [Century Therapeutics Inc, IPSC] show that its last 5-days average volume of 0.96 million was superior to 0.31 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 5.13%. Additionally, its Average True Range was 0.14.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 2.88%, which indicates a significant decrease from 5.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 110.76% in the past 14 days, which was higher than the 83.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4050, while its 200-day Moving Average is $2.4474. Now, the first resistance to watch is $1.2400. This is followed by the second major resistance level at $1.3100. The third major resistance level sits at $1.3650. If the price goes on to break the first support level at $1.1150, it is likely to go to the next support level at $1.0600. The third support level lies at $0.9900 if the price breaches the second support level.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
With a market capitalization of 99.48 million, the company has a total of 85,029K Shares Outstanding. Currently, annual sales are 2,240 K while annual income is -136,670 K. The company’s previous quarter sales were 790 K while its latest quarter income was -31,230 K.
